Market Place
Sourcing Support
NurExone Wins First Place in Healthcare at BOLD Awards VII
01 Apr 2026 //
GLOBENEWSWIRE
NurExone Expands Manufacturing Via Exo-Top Sublicense
26 Mar 2026 //
GLOBENEWSWIRE
NurExone Announces Corporate Updates
11 Mar 2026 //
GLOBENEWSWIRE
NurExone to Show Regenerative Medicine Platform at NANO.IL.2026
27 Feb 2026 //
GLOBENEWSWIRE
Nurexone Appoints Eyal Gabbai to Healthcare Board
30 Jan 2026 //
GLOBENEWSWIRE
Nurexone Demonstrates Exosome Anti-Inflammatory Activity In Lab
19 Dec 2025 //
GLOBENEWSWIRE
NurExone Initiates Small-Scale ExoPTEN Clinical Manufacturing
12 Dec 2025 //
GLOBENEWSWIRE
Nurexone Biologic Reveals Q3 2025 Financials & Corporate Update
28 Nov 2025 //
GLOBENEWSWIRE
Nurexone Joins Armi Biofab Lab Strengthening US Regenerative Work
03 Nov 2025 //
GLOBENEWSWIRE
Nurexone Invited Presenter At Precision EV Forum In Cambridge, UK
21 Oct 2025 //
GLOBENEWSWIRE
Nurexone Shows Consistent Vision Improvement In Glaucoma Model
08 Oct 2025 //
GLOBENEWSWIRE
NurExone to Set Up First US Commercial Manufacturing Facility
16 Sep 2025 //
GLOBENEWSWIRE
NurExone Announces Israel Patent Grant & Private Placement
11 Sep 2025 //
GLOBENEWSWIRE
NurExone Gets Patent for Exosome Production, Boosts Supply Chain
08 Sep 2025 //
GLOBENEWSWIRE
NurExone Biologic Reveals Q2 2025 Financials Result
28 Aug 2025 //
GLOBENEWSWIRE
NurExone`s Preclinical Proof of Spinal Cord Repair with ExoPTEN
20 Aug 2025 //
GLOBENEWSWIRE
NurExone Biologic named finalist in Falling Walls Venture 2025
25 Jul 2025 //
GLOBENEWSWIRE
ExoPTEN Study Shows Walking Improvement in Spinal Cord Injury
08 Jul 2025 //
GLOBENEWSWIRE
NurExone Joins ARMI HealthTech Hub Accelerator, Updates Strategy
20 Jun 2025 //
GLOBENEWSWIRE
NurExone Advances ExoPTEN Trials with New Process Validation
04 Jun 2025 //
GLOBENEWSWIRE
NurExone Reveals Trials Plan for Spinal Cord Injury Therapy
30 May 2025 //
GLOBENEWSWIRE
NurExone Biologic Announces Q1 2025 Results & Update
27 May 2025 //
GLOBENEWSWIRE
NurExone Presents Preclinical Data at ARVO 2025
08 May 2025 //
GLOBENEWSWIRE
NurExone Expands European Engagement with Investor Events
02 May 2025 //
GLOBENEWSWIRE
NurExone to Showcase Facial Nerve Regeneration at ISEV 2025
24 Apr 2025 //
GLOBENEWSWIRE
NurExone Appoints Jacob Licht, Expands in U.S. and Ontario
22 Apr 2025 //
GLOBENEWSWIRE
NurExone Biologic Inc. Announces Q4 and Full-Year 2024 Financial
09 Apr 2025 //
GLOBENEWSWIRE
NurExone Biologic Announces US Uplisting Intention & Closes C$2.3 M
04 Apr 2025 //
GLOBENEWSWIRE
NurExone To Present At MIXiii 2025; Prof Belkin Wins Lifetime Award
27 Feb 2025 //
GLOBENEWSWIRE
NurExone Biologic: 2025 TSX Venture 50™ Top Performer
19 Feb 2025 //
GLOBENEWSWIRE
NurExone Biologic Expands US Presence With Conference Talk
14 Feb 2025 //
GLOBENEWSWIRE
NurExone Forms Exo-Top in US for Manufacture & Commercialization
05 Feb 2025 //
GLOBENEWSWIRE
NurExone Raises C$1.2M, Appoints New R&D Director
22 Jan 2025 //
GLOBENEWSWIRE
NurExone Biologic Secures Master Cell Bank
08 Jan 2025 //
GLOBENEWSWIRE
NurExone Biologic Closes Final Private Placement Tranche
01 Nov 2024 //
GLOBENEWSWIRE
NurExone Biologic Announces Private Placement Of Up To $2M
26 Sep 2024 //
GLOBENEWSWIRE
NurExone Biologic Reaches Milestone In Exosome Manufacturing Process
15 Aug 2024 //
GLOBENEWSWIRE
NurExone`s ExoPTEN Shows Targeting Ability In New Study
09 Aug 2024 //
GLOBENEWSWIRE
NurExone Transfers ExoPTEN Drug Manufacturing To GMP Manufacturer
01 Aug 2024 //
GLOBENEWSWIRE
NurExone Engages Expert Biological Drug Development
21 Jun 2024 //
GLOBENEWSWIRE
NurExone Presenting Regulatory Pathways for Exosomes Therapies at Global Summit
01 Mar 2024 //
GLOBENEWSWIRE
NurExone Launches Licensing Efforts for ExoTherapy Platform
14 Feb 2024 //
GLOBENEWSWIRE
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury
05 Oct 2023 //
GLOBENEWSWIRE
NurExone Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN
20 Mar 2023 //
GLOBENEWSWIRE
NurExone Announces Interim Positive Results of Proprietary ExoPTEN Drug
17 Feb 2023 //
GLOBENEWSWIRE
NurExone Bio Emerges as a Promising Investment Opportunity in Biotechnology
13 Feb 2023 //
GLOBENEWSWIRE
